Inventiva
Price & Volume
Stats
See more52W Range | $1.53-$4.05 |
Market Cap | $374M |
Shares Short | 340,563 |
Financials
See moreRevenue (12 Mos) | $14M |
Revenue Growth (YoY) | -29.9% |
Gross Profit (12 Mos) | $12.6M |
Diluted EPS | -$3.55 |
News
See moreYahoo Finance • last year
Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023
Yahoo Finance • 2 years ago
Inventiva announces positive topline results from the investigator-initiated Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD
Yahoo Finance • 3 years ago
Inventiva announces the screening of the first patient in LEGEND, a Phase IIa combination trial with lanifibranor and empagliflozin in patients with NASH and T2D
Yahoo Finance • 3 years ago
Update on Inventiva's cash position and on the finance documentation with the European Investment Bank
About
CEO | Mr. Frederic Cren |
CFO | Mr. Jean Volatier |
Address | 50 rue de Dijon, Daix, France, 21121 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 114 |
